arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Edesa Biotech, Inc.

EDSA

$2.14 ▼ -0.07 (-3.17%) at close

14 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Edesa Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.1M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -63.5% ↗

FCF / Share $-1.29 ↗

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$328.80K

↑ +55.2% —

Net Income Profit after all expenses

$-7.19M

↓ -16.5% —

FCF / Share Free cash flow per share

$-1.29

↑ +15.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	55.2% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+590%)	-7.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-190%)	-82.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1126%)	67.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+745%)	103.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1198%)	-31.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-497%)	90.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1034%)	—	—
EPS Growth YoY (%)	34.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	-58.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	67.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-16.5% Weak ↓ Weak Declining Year-over-year change in net income	26.3% Excellent ↑ Excellent Improving Year-over-year change in net income	52.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-31.5% Weak ↑ Weak Improving Year-over-year change in net income	-109.7% Weak ↓ Weak Declining Year-over-year change in net income	-26.3% Weak → Weak Stable Year-over-year change in net income	-0.2% Weak ↑ Weak Improving Year-over-year change in net income	-0.1% Weak ↓ Weak Declining Year-over-year change in net income	-76.8% Weak ↓ Weak Declining Year-over-year change in net income	66.3% Excellent ↑ Excellent Improving Year-over-year change in net income	41.8% Excellent Excellent Year-over-year change in net income	-162.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	15.7% Good Good Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	—	-36.3% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-34.6% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-15.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	32.6% Excellent Excellent Compound annual revenue growth over 3 years	38.4% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	—	—	—	—	—	-2.4% Weak ↑ Weak Improving Compound annual revenue growth over 5 years	-17.2% Weak Weak Compound annual revenue growth over 5 years	-4.4% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	-386.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2673%)	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	-395.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3394%)	-374.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3223%)	—	—	—	—
FCF / Net Income (x)	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Return on Invested Capital (%)	-63.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-354.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-130.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-195.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-181.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-96.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-55.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-42.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-58.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-183.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-103.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-158.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-162.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-43.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-67.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-41.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-57.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-485%)	—	-118.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-892%)	-186.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1346%)	-102.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-781%)	-121.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-907%)	-44.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-398%)	-68.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-553%)	-40.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-372%)	-35.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-337%)	-109.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-831%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Net Debt (USD)	$-10.80M	$-1.00M	$-5.40M	$-7.09M	$-7.84M	$-5.03M	$-4.23M	$-4.57M	$-7.42M	$-3.96M	$-8.42M	$-7.86M	$-999.00K	$-4.15M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	—	$0.14	$0.10	$0.05	—	—	—
Basic EPS, GAAP (USD)	$-1.27	$-1.93	—	—	—	—	—	—	$-0.57	$-0.36	$-1.11	—	—	—
Free Cash Flow per Share (USD)	$-1.29	$-1.53	—	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$1.74	$0.61	$2.96	$0.56	$0.98	$0.55	$2.12	$4.92	$1.21	$1.00	$0.98	$-0.04	—	—
Tangible Book Value per Share (USD)	$1.74	$0.61	$2.96	$0.56	$0.98	$0.55	$2.12	$4.92	$1.21	$1.00	$0.98	$-0.04	—	—
Basic Weighted Avg Shares (shares)	5.68M	3.20M	—	—	—	—	—	—	8.83M	7.96M	7.58M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Working Capital (USD)	$10.43M	$-157.21K	$4.61M	$6.95M	$10.63M	$6.57M	$10.16M	$6.44M	$11.48M	$7.49M	$12.65M	$4.26M	—	—
Total Equity (USD)	$12.45M	$1.98M	$7.05M	$9.39M	$13.06M	$5.26M	$11.29M	$7.40M	$12.31M	$8.01M	$7.70M	$-2.20M	$902.16K	$3.44M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2018 10-K ↗	FY 2018 Sep 30, 2017 10-K ↗	FY 2017 Sep 30, 2016 10-K ↗	FY 2016 Sep 30, 2015 10-K ↗	FY 2015 Aug 31, 2014 10-K ↗	FY 2014 Aug 31, 2013 10-K ↗	FY 2013 Aug 31, 2012 10-K ↗	FY 2012 Aug 31, 2011 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	$328.80K	$211.85K	$228.29K	$1.27M	$758.69K	$372.13K	$545.47K	$286.05K	—
Depreciation Expense (USD)	$119.27K	$186.05K	$4.33B	$6.99B	$8.32B	$9.60B	$188.37K	$179.32K	$149.56K	$159.52K	$158.31K	$124.83K	$112.14K	—
Net Income, GAAP (USD)	$-7.19M	$-6.17M	$-8.37M	$-17.55M	$-13.34M	$-6.36M	$-5.04M	$-5.03M	$-5.03M	$-2.84M	$-8.44M	$-14.50M	$-5.53M	—
Operating Cash Flow (USD)	$-7.32M	$-4.89M	$-6.64M	$-12.28M	$-13.66M	$-4.99M	$-4.62M	$-4.70M	—	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 51 quarters

Edesa Biotech, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare EDSA with peers